Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece

被引：0
|
作者：
Hara Kousoulakou
Magdalini Hatzikou
Varvara Baroutsou
John Yfantopoulos
机构：
[1] University of Peloponnese,
[2] Novartis Hellas SACI,undefined
[3] National and Kapodistrian University of Athens,undefined
[4] School of Economics and Political Science ,undefined
来源：
Cost Effectiveness and Resource Allocation | / 15卷
关键词：
Vildagliptin; Type 2 diabetes mellitus; Cost-effectiveness; Greece;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Long-term efficacy and safety of add-on therapy of vildagliptin in type 2 diabetes mellitus with insulin treatment
    Kanazawa, Ippei
    Tanaka, Ken-ichiro
    Notsu, Masakazu
    Tanaka, Sayuri
    Kiyohara, Nobuaki
    Koike, Sayo
    Yamane, Yuko
    Tada, Yuko
    Sasaki, Motofumi
    Yamauchi, Mika
    Sugimoto, Toshitsugu
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S107 - S107
  • [42] COST-EFFECTIVENESS OF FIXED-DOSE COMBINATION (FDC) OF VILDAGLIPTIN/METFORMIN FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2 IN MEXICO
    Lemus, A.
    Jimenez Aranda, P.
    VALUE IN HEALTH, 2013, 16 (07) : A689 - A689
  • [43] COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS ADD-ON TO INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES IN THE NETHERLANDS
    van Haalen, H. G. M.
    Pompen, M.
    Bergenheim, K.
    McEwan, P.
    Townsend, R.
    Roudaut, M.
    VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [44] Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment
    Kanazawa, Ippei
    Tanaka, Ken-ichiro
    Notsu, Masakazu
    Tanaka, Sayuri
    Kiyohara, Nobuaki
    Koike, Sayo
    Yamane, Yuko
    Tada, Yuko
    Sasaki, Motofumi
    Yamauchi, Mika
    Sugimoto, Toshitsugu
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2017, 123 : 9 - 17
  • [45] Comparison of the Effectiveness and Safety of Vildagliptin Add-On to Metformin Versus Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes: The China Prospective Diabetes Study
    Zang, Li
    Han, Yin
    Chen, Lixian
    Hu, Daqing
    Jin, Hui
    Yang, Nailong
    Shi, Xiaoyun
    Liang, Linlang
    Liu, Mingming
    Fan, Hong
    Li, Quanmin
    Mu, Yiming
    DIABETES THERAPY, 2019, 10 (04) : 1391 - 1405
  • [46] Comparison of the Effectiveness and Safety of Vildagliptin Add-On to Metformin Versus Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes: The China Prospective Diabetes Study
    Li Zang
    Yin Han
    Lixian Chen
    Daqing Hu
    Hui Jin
    Nailong Yang
    Xiaoyun Shi
    Linlang Liang
    Mingming Liu
    Hong Fan
    Quanmin Li
    Yiming Mu
    Diabetes Therapy, 2019, 10 : 1391 - 1405
  • [47] Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany
    Goke, R.
    Gruenberger, J. B.
    Bader, G.
    Dworak, M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (05) : 785 - 789
  • [48] A cost-effectiveness analysis of linagliptin add-on to insulin treatment for patients with type 2 diabetes mellitus and chronic kidney disease in Iran
    Fariman, Soroush Ahmadi
    Nosrati, Marzieh
    Rahmani, Parham
    Nikfar, Shekoufeh
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2023, 22 (02) : 1263 - 1271
  • [49] Vildagliptin Versus α-Glucosidase Inhibitor as Add-On to Metformin for Type 2 Diabetes: Subgroup Analysis of the China Prospective Diabetes Study
    Chen, Yulong
    Li, Quanmin
    Han, Ying
    Ji, Hongmei
    Gu, Mingjun
    Bian, Rongwen
    Ding, Weiguang
    Cheng, Jian
    Mu, Yiming
    DIABETES THERAPY, 2020, 11 (01) : 247 - 257
  • [50] Cost Effectiveness of Saxagliptin and Metformin versus Sulfonylurea and Metformin in the Treatment of Type 2 Diabetes Mellitus in Germany A Cardiff Diabetes Model Analysis
    Erhardt, Wilma
    Bergenheim, Klas
    Duprat-Lomon, Isabelle
    McEwan, Phil
    CLINICAL DRUG INVESTIGATION, 2012, 32 (03) : 189 - 202
12345